LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
33 hedge funds and large institutions have $124M invested in LogicBio Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 6 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $131M → $124M (-$6.97M)
8% less funds holding
Funds holding: 36 → 33 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$789K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$506K |
| 3 |
Bank of New York Mellon
New York
|
+$214K |
| 4 |
State Street
Boston,
Massachusetts
|
+$77.6K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
+$54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$675K |
| 2 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$578K |
| 3 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$543K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$156K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$146K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
26
STRS Ohio
Columbus,
Ohio
| $21K | – | – | – |
|
27
Citigroup
New York
| $21K | +$14.9K | +1,600 | +327% |
|
28
JP Morgan Chase
New York
| $20K | -$4.31K | -463 | -19% |
|
29
Morgan Stanley
New York
| $14K | -$102K | -10,985 | -88% |
|
30
Legal & General Group
London,
United Kingdom
| $12K | – | – | – |
|
|
AIP
31
Ameritas Investment Partners
Lincoln,
Nebraska
| $7K | – | – | – |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $6K | +$5.67K | +609 | New |
|
|
33
Goldman Sachs
New York
| – | -$675K | -64,949 | Closed |
|
|
LCM
34
Landscape Capital Management
Englewood,
New Jersey
| – | -$578K | -55,597 | Closed |
|
|
DIM
35
DC Investments Management
Mclean,
Virginia
| – | -$543K | -52,174 | Closed |
|
|
LCM
36
Laurion Capital Management
New York
| – | -$156K | -15,000 | Closed |
|
|
37
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$146K | -14,068 | Closed |
|
38
UBS Group
Zurich,
Switzerland
| – | -$27.5K | -2,956 | -98% |
|
|
CCA
39
Catalyst Capital Advisors
Huntington,
New York
| – | -$6K | -620 | Closed |
|
LOGC Hedge Fund Activity: Q1 2019 in Review
33 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q1 2019, worth a combined $124M — down 5.3% from $131M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LOGC and 3 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 10 added.
The largest buyer was Samlyn Capital, adding an estimated $789K. The largest seller was Goldman Sachs, exiting entirely with an estimated $675K sold.
- 33 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q1 2019, down from 36 in Q4 2018.
- Funds reported $124M of LogicBio Therapeutics, Inc. Common Stock stock for Q1 2019, down 5.3% quarter-over-quarter.
- 3 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q1 2019 and 6 closed out, a net change of -3 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q1 2019 was Samlyn Capital, an estimated $789K added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q1 2019 was Goldman Sachs, an estimated $675K sold.
Based on aggregated 13F filings for Q1 2019.